Supporting pharma and biotech companies with advanced human-relevant models for neuroscience drug development.
Pharmaceutical and biotech companies working in neuroscience face one of the most complex areas of drug development. Candidate compounds must be evaluated in biological systems that can provide meaningful insights into human neuronal activity, disease mechanisms, safety and potential therapeutic response.
Traditional preclinical models can be limited in their ability to reproduce the complexity of the human nervous system. This can create uncertainty during early development and increase the risk of advancing candidates with insufficient translational evidence.
AxCellerate supports pharma and biotech teams with Brain-on-Chip technology based on three-dimensional human-derived neuronal models. Our platform is designed to help companies assess new chemical entities, investigate disease-related mechanisms, validate therapeutic targets and generate early evidence to support internal R&D decisions.
AxCellerate’s Brain-on-Chip platform provides a more human-relevant environment to study neuronal response and compound behaviour in preclinical research.
For pharma and biotech companies, this can support:
Three-dimensional human-derived neuronal models help bridge the gap between conventional preclinical systems and human biology.
The platform can support the identification of potential safety issues, neurotoxic effects or limited biological response earlier in the development cycle.
Electrophysiological recording capabilities provide valuable insights into neuronal activity and compound effects on neural networks.
Therapeutic targets can be investigated in a more biologically relevant neuronal environment before further development decisions are made.
When a suitable model is available, AxCellerate can support disease modelling and efficacy-related assessments in neuroscience programs.
Each collaboration is structured around the client’s compound, target, disease area and research objective.
AxCellerate works with pharma and biotech teams as a scientific and technological partner, supporting preclinical research programs with tailored experimental strategies.
Our services can contribute to different stages of neuroscience drug discovery and development, including compound evaluation, disease modelling, safety assessment, target validation and translational research.
The goal is to provide clearer, more relevant data that helps teams prioritize candidates, reduce uncertainty and move forward with greater confidence.
